228 related articles for article (PubMed ID: 33316293)
1. Divergent profiles of fentanyl withdrawal and associated pain in mice and rats.
Uddin O; Jenne C; Fox ME; Arakawa K; Keller A; Cramer N
Pharmacol Biochem Behav; 2021 Jan; 200():173077. PubMed ID: 33316293
[TBL] [Abstract][Full Text] [Related]
2. The effects of buprenorphine on fentanyl withdrawal in rats.
Bruijnzeel AW; Marcinkiewcz C; Isaac S; Booth MM; Dennis DM; Gold MS
Psychopharmacology (Berl); 2007 May; 191(4):931-41. PubMed ID: 17211652
[TBL] [Abstract][Full Text] [Related]
3. In vivo and in vitro attenuation of naloxone-precipitated experimental opioid withdrawal syndrome by insulin and selective KATP channel modulator.
Singh P; Sharma B; Gupta S; Sharma BM
Psychopharmacology (Berl); 2015 Jan; 232(2):465-75. PubMed ID: 25059539
[TBL] [Abstract][Full Text] [Related]
4. Probing different paradigms of morphine withdrawal on sleep behavior in male and female C57BL/6J mice.
Bedard ML; Lord JS; Perez PJ; Bravo IM; Teklezghi AT; Tarantino LM; Diering GH; McElligott ZA
Behav Brain Res; 2023 Jun; 448():114441. PubMed ID: 37075956
[TBL] [Abstract][Full Text] [Related]
5. Effects of fentanyl dose and exposure duration on the affective and somatic signs of fentanyl withdrawal in rats.
Liu J; Pan H; Gold MS; Derendorf H; Bruijnzeel AW
Neuropharmacology; 2008 Oct; 55(5):812-8. PubMed ID: 18634811
[TBL] [Abstract][Full Text] [Related]
6. Xylazine suppresses fentanyl consumption during self-administration and induces a unique sex-specific withdrawal syndrome that is not altered by naloxone in rats.
Khatri SN; Sadek S; Kendrick PT; Bondy EO; Hong M; Pauss S; Luo D; Prisinzano TE; Dunn KE; Marusich JA; Beckmann JS; Hinds TD; Gipson CD
Exp Clin Psychopharmacol; 2024 Apr; 32(2):150-157. PubMed ID: 37470999
[TBL] [Abstract][Full Text] [Related]
7. Sphingosine-1-phosphate receptor subtype 1 activation in the central nervous system contributes to morphine withdrawal in rodents.
Doyle TM; Hutchinson MR; Braden K; Janes K; Staikopoulos V; Chen Z; Neumann WL; Spiegel S; Salvemini D
J Neuroinflammation; 2020 Oct; 17(1):314. PubMed ID: 33092620
[TBL] [Abstract][Full Text] [Related]
8. The relative potency of inverse opioid agonists and a neutral opioid antagonist in precipitated withdrawal and antagonism of analgesia and toxicity.
Sirohi S; Dighe SV; Madia PA; Yoburn BC
J Pharmacol Exp Ther; 2009 Aug; 330(2):513-9. PubMed ID: 19435929
[TBL] [Abstract][Full Text] [Related]
9. Methocinnamox Produces Long-Lasting Antagonism of the Behavioral Effects of
Gerak LR; Minervini V; Latham E; Ghodrati S; Lillis KV; Wooden J; Disney A; Husbands SM; France CP
J Pharmacol Exp Ther; 2019 Nov; 371(2):507-516. PubMed ID: 31439807
[TBL] [Abstract][Full Text] [Related]
10. Analgesic effects of systemic fentanyl on cancer pain are mediated by not only central but also peripheral opioid receptors in mice.
Shinohara A; Andoh T; Saiki I; Kuraishi Y
Eur J Pharmacol; 2018 Aug; 833():275-282. PubMed ID: 29886241
[TBL] [Abstract][Full Text] [Related]
11. Disulfiram attenuates morphine or methadone withdrawal syndrome in mice.
de Cordé A; Krząścik P; Wolińska R; Kleczkowska P; Filip M; Bujalska-Zadrożny M
Behav Pharmacol; 2018 Aug; 29(5):393-399. PubMed ID: 29462108
[TBL] [Abstract][Full Text] [Related]
12. Naloxone rapidly evokes endogenous kappa opioid receptor-mediated hyperalgesia in naïve mice pretreated briefly with GM1 ganglioside or in chronic morphine-dependent mice.
Crain SM; Shen KF
Brain Res; 2007 Sep; 1167():31-41. PubMed ID: 17692296
[TBL] [Abstract][Full Text] [Related]
13. Method for Successfully Inducting Individuals Who Use Illicit Fentanyl Onto Buprenorphine/Naloxone.
Antoine D; Huhn AS; Strain EC; Turner G; Jardot J; Hammond AS; Dunn KE
Am J Addict; 2021 Jan; 30(1):83-87. PubMed ID: 32572978
[TBL] [Abstract][Full Text] [Related]
14. Role of gabapentin in preventing fentanyl- and morphine-withdrawal-induced hyperalgesia in rats.
Wei X; Wei W
J Anesth; 2012 Apr; 26(2):236-41. PubMed ID: 22048285
[TBL] [Abstract][Full Text] [Related]
15. Involvement of neuropeptide FF receptors in neuroadaptive responses to acute and chronic opiate treatments.
Elhabazi K; Trigo JM; Mollereau C; Moulédous L; Zajac JM; Bihel F; Schmitt M; Bourguignon JJ; Meziane H; Petit-demoulière B; Bockel F; Maldonado R; Simonin F
Br J Pharmacol; 2012 Jan; 165(2):424-35. PubMed ID: 21718302
[TBL] [Abstract][Full Text] [Related]
16. Anxiogenic-like effects of opiate withdrawal seen in the fear-potentiated startle test, an interdisciplinary probe for drug-related motivational states.
Fendt M; Mucha RF
Psychopharmacology (Berl); 2001 May; 155(3):242-50. PubMed ID: 11432686
[TBL] [Abstract][Full Text] [Related]
17. Quantitative evaluation of opioid withdrawal signs in rats repeatedly treated with morphine and injected with naloxone, in the absence or presence of the antiabstinence agent clonidine.
Pinelli A; Trivulzio S
J Pharmacol Toxicol Methods; 1997 Nov; 38(3):117-31. PubMed ID: 9523765
[TBL] [Abstract][Full Text] [Related]
18. Inhibitory transmission in the bed nucleus of the stria terminalis in male and female mice following morphine withdrawal.
Luster BR; Cogan ES; Schmidt KT; Pati D; Pina MM; Dange K; McElligott ZA
Addict Biol; 2020 May; 25(3):e12748. PubMed ID: 30963693
[TBL] [Abstract][Full Text] [Related]
19. Analgesic activity and pharmacological characterization of N-[1-phenylpyrazol-3-yl]-N-[1-(2-phenethyl)-4-piperidyl] propenamide, a new opioid agonist acting peripherally.
Goicoechea C; Sánchez E; Cano C; Jagerovic N; Martín MI
Eur J Pharmacol; 2008 Oct; 595(1-3):22-9. PubMed ID: 18706410
[TBL] [Abstract][Full Text] [Related]
20. A limited access oral oxycodone paradigm produces physical dependence and mesocorticolimbic region-dependent increases in DeltaFosB expression without preference.
Iyer V; Woodward TJ; Pacheco R; Hohmann AG
Neuropharmacology; 2022 Mar; 205():108925. PubMed ID: 34921830
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
